ArticleBMC nephrology2025
Clinical characteristics and short term outcomes of childhood immune complex membranoproliferative glomerulonephritis and C3 glomerulopathy: a single centre retrospective study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary membranoproliferative glomerulonephritis: natural history, pathogenesis, and treatment.Frontiers in nephrology · 2026Review
- An Unusual Case of Membranoproliferative Glomerulonephritis: Is the Role of Vaccination in Immune Reactivation a Casual or Causal Effect?Reports (MDPI) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMembranoproliferative glomerulonephritis, with its immune complex variety and C3 glomerulopathy, is a rare glomerular disease in children. The objective of this study was to determine the clinical features and short-term outcomes in children.
methodsThis retrospective cohort study was conducted at the Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation, Karachi, from January 2020, to June 2022. All the children with membranoproliferative lesions identified via light microscopy and less than 18 years were included.
resultsA total of 35 children were diagnosed MPGN, 7 (20%) with C3 glomerulopathy and 28 (80%) idiopathic immune complex MPGN. In the IC-MPGN group, 14 patients (50%) had crescentic glomerulonephritis. Induction therapy consisted of cyclophosphamide and methylprednisolone followed by steroids, azathioprine was prescribed for maintenance phase. At the 18-month follow-up, 9 (64%) patients were in complete remission (CR), 3 (21%) were in partial remission (PR), and 2 (15%) progressed to chronic kidney disease. The remaining 14 (50%) had non-crescentic idiopathic IC-MPGN and were prescribed steroids only, cyclophosphamide with steroids and angiotensin converting enzyme inhibitors. The outcomes at 18 months were relatively poorer than those with the crescentic variety. Four (28%) patients achieved CR, 8 (56%) PR, and 2 (14%) did not respond. In the C3 glomerulopathy cohort, 3 (43%) had crescentic glomerulonephritis, one child was in CR, and two were in PR. The non-crescentic C3G were kept on ACEI 3 (43%) and Mycophenolate mofetil 1 (14%). One child treated with ACEIs achieved a PR, two were in CR, and one child treated with MMF did not respond.
conclusionsThe outcome of MPGN (immune complex and C3G) is quite variable, and aggressive therapy for crescentic glomerulonephritis may show a favourable response. Considering the similar clinical presentations and patient outcomes, C3G and IC-MPGN might represent two facets of the same disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.